Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kinnate Biopharma Inc (KNTE)

Kinnate Biopharma Inc (KNTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,146
  • Shares Outstanding, K 47,225
  • Annual Sales, $ 0 K
  • Annual Income, $ -116,270 K
  • EBIT $ -135 M
  • EBITDA $ -138 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.78
  • Most Recent Earnings $-0.65 on 11/09/23
  • Next Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.43
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +50.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +5.16%
on 03/14/24
2.69 -1.49%
on 03/28/24
+0.06 (+2.32%)
since 03/01/24
3-Month
2.20 +20.45%
on 02/09/24
2.69 -1.49%
on 03/28/24
+0.16 (+6.43%)
since 01/02/24
52-Week
1.04 +154.81%
on 10/26/23
7.18 -63.12%
on 04/14/23
-3.60 (-57.60%)
since 03/31/23

Most Recent Stories

More News
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program...

KNTE : 2.65 (-0.38%)
S&P Futures Plunge Ahead of FOMC Meeting, Oil’s Climb Raises Inflation Concerns

December S&P 500 futures (ESZ23) are trending down -0.51% this morning as market participants geared up for a big week for central banks, with the spotlight on the Federal Reserve’s interest rate decision...

ESZ23 : 4,694.27s (-0.58%)
AAPL : 254.49 (+1.88%)
AYX : 48.26 (+0.02%)
TSLA : 421.06 (-3.46%)
ARM : 132.15 (+0.04%)
KGF.LN : 250.700 (+0.48%)
NIO : 4.54 (+3.18%)
DELL : 115.77 (+3.40%)
AVGR : 0.4826 (-32.61%)
KNTE : 2.65 (-0.38%)
GMED : 82.63 (+0.84%)
PLNT : 99.26 (+0.08%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 2.63 (-1.50%)
DAWN : 12.79 (+2.65%)
SWTX : 35.59 (+2.33%)
VSTM : 4.19 (-5.63%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 2.63 (-1.50%)
SWTX : 35.59 (+2.33%)
DAWN : 12.79 (+2.65%)
VSTM : 4.19 (-5.63%)
KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Preclinical data from a study of the Company’s pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248

SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Three poster presentations highlight the unmet need for targeted therapies in BRAF and/or NRAS-altered cancers, including non-small cell lung cancer and...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates

Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the...

KNTE : 2.65 (-0.38%)
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting

Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor program, KIN-2787...

KNTE : 2.65 (-0.38%)

Business Summary

Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate Biopharma Inc. is based in SAN FRANCISCO, California.

See More

Key Turning Points

3rd Resistance Point 2.70
2nd Resistance Point 2.69
1st Resistance Point 2.67
Last Price 2.65
1st Support Level 2.64
2nd Support Level 2.62
3rd Support Level 2.60

See More

52-Week High 7.18
Fibonacci 61.8% 4.84
Fibonacci 50% 4.11
Fibonacci 38.2% 3.39
Last Price 2.65
52-Week Low 1.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar